Biotechnology and Pharmaceuticals

March 18, 2021

Buy ($175)

Companies covered: Arcturus Therapeutics Ltd. (NASDAQ:ARCT), Vaxart (NASDAQ:VXRT), Veru (NASDAQ:VERU), Moderna (NASDAQ:MRNA), Pfizer, Inc. (NYSE:PFE), Johnson & Johnson (NYSE:JNJ), Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC), Atreca (NASDAQ:BCEL), BioCardia Inc. (NASDAQ:BCDA), Forte Biosciences Inc. (NASDAQ:FBRX), Caladrius Biosciences Inc. (NASDAQ:CLBS), Medicenna Therapeutics Corp. (NASDAQ:MDNA), SpringWorks Therapeutics (NASDAQ:SWTX), bluebird bio, Inc. (NASDAQ:BLUE), AVROBIO (NASDAQ:AVRO), Blueprint Medicines Corp. (NASDAQ:BPMC), Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY), Argenx SE (ADR) (NASDAQ:ARGX), Magenta Therapeutics Inc. (NASDAQ:MGTA), Scholar Rock Holding Corp. (NASDAQ:SRRK), Orchard Therapeutics PLC – ADR (NASDAQ:ORTX), Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH), Ortho Regenerative Technologies Inc. (OTCMKTS:ORTIF), Lantern Pharma Inc. (NASDAQ:LTRN), Kintara Therapeutics Inc. (NASDAQ:KTRA), DarioHealth Corp. (NASDAQ:DRIO), AnPac Bio-Medical Science Co Ltd – ADR (NASDAQ:ANPC), BiOasis Technologies Inc. (OTCMKTS:BIOAF), Protalix BioTherapeutics, Inc. (NYSEAMERICAN:PLX), electroCore, Inc. (NASDAQ:ECOR), MiMedx Group, Inc (NASDAQ:MDXG), Heat Biologics, Inc. (NASDAQ:HTBX), Achieve Life Sciences (NASDAQ:ACHV), Zoom Video Communications (NASDAQ:ZM), Amazon.com, Inc. (NASDAQ:AMZN), Walt Disney Company (The) (NYSE:DIS), Netflix, Inc. (NASDAQ:NFLX), Amarin Corporation PLC (NASDAQ:AMRN), Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Durect Corporation (NASDAQ:DRRX), Cancer Genetics, Inc. (NASDAQ:CGIX), Quick-Med Technologies Inc. (OTCMKTS:QMDT), VolitionRX Limited (NYSEAMERICAN:VNRX), NovelStem International Corp. (OTCMKTS:NSTM)